Ocular myasthenia gravis: controversies and updates

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) frequently begins with ocular symptoms (ocular MG or OMG).
• Predicting progression from OMG to generalized MG (SGMG) remains a clinical challenge.

Purpose of the Study:

• To review clinical predictors for SGMG development in OMG patients.
• To evaluate the role of early immunosuppressive therapies, including corticosteroids, in modifying SGMG risk.
• To discuss recent advancements in serological diagnostics for MG.

Main Methods:

• Literature review of retrospective studies on OMG progression.
• Analysis of evidence for risk-modifying effects of early corticosteroid treatment.
• Review of emerging immunosuppressive agents and thymectomy data for OMG.
• Examination of recent serological findings in seronegative and specific antibody-associated MG.

Main Results:

• Clinical features at onset may help predict SGMG risk, though a definitive prognostic model is lacking.
• Early corticosteroid use may influence SGMG development, but evidence is limited by study heterogeneity.
• Thymectomy shows potential benefit in some OMG cases.
• New antibodies (e.g., LRP4, clustered AChR) are identified in previously seronegative patients.

Conclusions:

• Further research is needed to establish reliable prognostic models for OMG progression.
• Optimal timing and impact of early immunosuppressive therapies require clarification.
• Advancements in serology are improving diagnostic capabilities for various MG subtypes.